Shire plc : Directorate change
(Thomson Reuters ONE) -
Shire to Appoint Thomas Dittrich as Chief Financial Officer and Member of the
Board of Directors
November 20, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG), the global biotech
leader in rare diseases, today announced that Thomas Dittrich will join the
company as Chief Financial Officer, and become an Executive member of the Board
of Directors and a member of the Executive Committee. Thomas will assume his
roles at Shire in early 2018 following a transition period from his current
employer.
"Thomas's wealth of experience while leading the finance teams at numerous
multinational companies, including Amgen for several years, will be a tremendous
asset for Shire as we continue to execute as the leading global biotech focused
on rare diseases," said Dr. Flemming Ornskov, MD, MPH, Chief Executive Officer,
Shire. "His unique financial skillset and results-oriented mentality make him
the right person to lead Shire's finance function."
Thomas is currently Chief Financial Officer and a member of the Executive
Committee at Sulzer Ltd, a publicly-listed, global industrial engineering and
manufacturing company. He joined Sulzer in August 2014, serving as Chief
Executive Officer ad interim between August 2015 and December 2015. At Sulzer,
he was instrumental in designing the company's transformation program and drove
key upgrades to finance and IT functions, as well as to capital structure and
resource allocation initiatives.
Prior to joining Sulzer, Thomas served as Vice President, Finance Corporate
Planning and Chief Accounting Officer of Amgen Inc. between 2010 and 2014.
Between 2006 and 2010, he was Vice President, Finance and Chief Financial
Officer of Amgen International. Thomas also spent eight years with Dell where he
held various finance and general manager roles. Earlier in his career, Thomas
worked at Booz & Co and Helbing Management Consulting AG in operational and
merger and acquisition roles, respectively.
"Thomas is a talented global executive who will bring to Shire a broad range of
experiences from both inside and outside the pharmaceutical industry," said
Susan Kilsby, Chairman of the Board at Shire. "The Board and I look forward to
working with him during this transformational time in the Company's history."
"I am thrilled to join Shire at such an exciting time in the Company's
evolution," said Thomas Dittrich. "I look forward to working with the Board, the
Executive Committee and the Finance organization as we build upon Shire's strong
fundamentals to drive future growth and shareholder value."
For further information please contact:
Investor Relations
Ian Karp ikarp(at)shire.com +1 781 482 9018
Robert Coates rcoates(at)shire.com +44 203 549 0874
Media
Amy Ryan aryan0(at)shire.com +1 617 588 8687
Katie Joyce kjoyce(at)shire.com +1 781 482 2779
NOTES TO EDITORS
No further information is required to be disclosed pursuant to 9.6.13R of the UK
Listing Rules.
About Shire
Shire is the leading global biotechnology company focused on serving people with
rare diseases. We strive to develop best-in-class products, many of which are
available in more than 100 countries, across core therapeutic areas including
Immunology, Hereditary Angioedema, Hematology, Lysosomal Storage Disorders,
Gastrointestinal / Internal Medicine / Endocrine, Ophthalmics, a growing
franchise in Oncology, and Neuroscience.
Our employees come to work every day with a shared mission: to develop and
deliver breakthrough therapies for the hundreds of millions of people in the
world affected by rare diseases and other high-need conditions, and who lack
effective therapies to live their lives to the fullest.
www.shire.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Shire plc via GlobeNewswire
Datum: 20.11.2017 - 14:00 Uhr
Sprache: Deutsch
News-ID 568858
Anzahl Zeichen: 4781
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 203 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Shire plc : Directorate change"
steht unter der journalistisch-redaktionellen Verantwortung von
Shire plc (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
